PAXLOVID is a prescription treatment for mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. PAXLOVID is also authorized for certain people under an Emergency Use Authorization. Learn more. Who can …

2024年11月14日 · Paxlovid is an antiviral treatment for COVID-19 used to lower the risk of severe COVID-19, including hospitalization or death. Paxlovid contains nirmatrelvir tablets and ritonavir packaged together.

Review these instructions so you can take PAXLOVID with confidence. Each pack contains several blister cards with your morning and evening doses of PAXLOVID. Each dose contains 2 types of medicine: nirmatrelvir tablets (pink) and a ritonavir tablet (white to off-white).

PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. There are two different dose packs available: • PAXLOVID (nirmatrelvir; ritonavir) co-packaged for oral use 300 mg;100 mg...

2024年12月12日 · Detailed dosage guidelines and administration information for Paxlovid (nirmatrelvir and ritonavir). Includes dose adjustments, warnings and precautions.

• PAXLOVID is available in 3 Dose Packs (see Figures A, B, and C below). Your healthcare provider will prescribe the PAXLOVID Dose Pack that is right for you.

PAXLOVID tablets Standard dose pack. The standard dose of PAXLOVID is 300 mg nirmatrelvir with 100 mg ritonavir taken together orally twice daily for 5 days; Each dose consists of two 150 mg nirmatrelvir tablets and one 100 mg ritonavir tablet

PAXLOVID consists of 2 medicines: nirmatrelvir and ritonavir. If you are prescribed the standard dose pack (300 mg nirmatrelvir; 100 mg ritonavir): Take 2 pink tablets of nirmatrelvir with 1 white to off-white tablet of ritonavir by mouth 2 times each day (in the morning and in the evening) for 5 …

See risks & benefits. Learn about PAXLOVID™, an emergency use authorized oral Rx that helps stop mild-to-moderate COVID-19 from becoming severe.

PAXLOVID is a medicine that is available under EUA for the treatment of mild-to-moderate COVID-19 in adults and children 12 years of age and older weighing at least 88 pounds (40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death.